← BridgeBio Pharma, Inc.
| Annual Trend | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $39k |
$2.0m
+5038.46%
|
$40.6m
+1923.95%
|
$8.2m
-79.66%
|
$69.7m
+745.14%
|
$77.6m
+11.38%
|
$9.3m
-88.02%
|
$221.9m
+2285.27%
|
$502.1m
+126.26%
|
— | $580.0m | |
| Cost of Revenue | — | — | $212.4m |
$481.8m
+126.79%
|
$2.7m
-99.43%
|
$3.4m
+25.56%
|
$2.4m
-28.77%
|
$3.9m
+58.54%
|
$21.0m
+440.54%
|
— | $28.3m | |
| Gross Profit (Calculated) (derived) | — | — | ($171.9m) |
($473.6m)
-175.51%
|
$67.0m
+114.14%
|
$74.2m
+10.80%
|
$6.9m
-90.76%
|
$218.0m
+3079.58%
|
$481.1m
+120.67%
|
— | — | |
| Research and Development Expense | $30.6m | $140.1m | $209.9m | $337.0m | $451.0m | $399.5m | $455.7m | $506.5m | $452.0m | $86k | $467.2m | |
| Selling, General and Administrative Expense | — | — | $94.4m | $924k | $192.2m | $143.2m | $150.6m | $288.9m | $531.2m | $204k | $588.8m | |
| Amortization of Intangible Assets | — | — | — | $986k | $2.6m | $2.4m | $2.4m | $2.4m | $2.7m | — | — | |
| Restructuring, impairment, and related charges | — | — | — | — | — | — | $7.9m | $15.6m | $21.3m | — | — | |
| Operating Expenses | — | $183.7m | $306.8m | $482.7m | — | — | — | — | — | — | $1.1b | |
| Total operating costs and expenses | — | — | $306.8m | $482.7m | $646.3m | $589.9m | $616.7m | $814.9m | $1.0b | — | — | |
| Loss from operations | ($43.9m) |
($183.7m)
-318.76%
|
($266.2m)
-44.96%
|
($474.5m)
-78.22%
|
($576.6m)
-21.53%
|
($512.2m)
+11.17%
|
($607.4m)
-18.58%
|
($593.0m)
+2.37%
|
($523.4m)
+11.73%
|
($1.6m)
+99.69%
|
— | |
| Operating Income (Loss) | ($43.9m) |
($183.7m)
-318.76%
|
($266.2m)
-44.96%
|
($474.5m)
-78.22%
|
($576.6m)
-21.53%
|
($512.2m)
+11.17%
|
($607.4m)
-18.58%
|
($593.0m)
+2.37%
|
($523.4m)
+11.73%
|
($1.6m)
+99.69%
|
($504.2m)
-31261.93%
|
|
| Interest Expense, Debt | — | — | — | — | $32.6m | $34.1m | $34.2m | $34.3m | — | — | $188.9m | |
| Noncash interest expense on deferred royalty obligations | — | — | — | — | — | — | $0 | ($8.3m) | ($125.1m) | — | — | |
| Interest income | $39k | $2.0m | $8.9m | $4.0m | $1.1m | $7.5m | $18.0m | $17.2m | $19.9m | — | $20.7m | |
| Equity Securities, FV-NI, Realized Gain (Loss) | — | — | — | — | $2.2m | $3.7m | $8.7m | $8.1m | $0 | — | — | |
| Gain on sale of assets, net (Note 4) | — | — | — | — | — | $192k | $0 | $0 | — | — | — | |
| Gain (loss) on sale/abandonment of assets, net (Notes 4 and 5) | — | — | — | ($1.3m) | $804k | $192k | — | — | — | — | — | |
| Other Nonoperating Income (Expense) | — | ($4.3m) | ($1.6m) | $1.6m | $35.8m | ($7.5m) | $17.4m | $12.3m | $43.1m | $679 | — | |
| Income (Loss) from Equity Method Investments | — | ($275k) | ($20.9m) | — | — | $0 | $0 | ($31.2m) | ($72.6m) | — | — | |
| Net loss from equity method investments | — | ($275k) | ($20.9m) | — | — | $0 | $0 | ($31.2m) | ($72.6m) | — | — | |
| Other income, net | — | ($4.3m) | ($1.6m) | $1.6m | $35.8m | ($7.5m) | $17.4m | $12.3m | $43.1m | $679 | ($57.0m) | |
| Non-Operating Income (Expense) | — | — | — | $48k | ($40k) | $27k | $18k | ($945) | $9 | ($679) | — | |
| Interest Expense (non-operating) | $13k | $2.5m | $8.8m | $36.7m | $46.8m | $80.4m | $81.3m | $99.3m | $53.1m | $154k | $188.9m | |
| Total other income (expense), net | $26k | $14.2m | ($22.3m) | ($31.0m) | ($9.8m) | $27.6m | ($45.9m) | $50.8m | ($209.1m) | — | — | |
| Total other income | — | — | — | ($10.3m) | ($28.4m) | ($1.8m) | $88k | $342k | $1.4m | $95k | — | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | — | $169.5m | $288.6m | $505.5m | ($586.5m) | ($485.1m) | ($565.8m) | ($207.8m) | ($437.6m) | — | ($729.5m) | |
| Loss before income taxes | — | — | — | — | — | ($484.7m) | ($653.3m) | ($542.2m) | ($732.5m) | — | — | |
| Net loss before income taxes | — | — | — | ($19.6m) | ($36.4m) | ($12.0m) | ($9.4m) | ($2.9m) | $732.5m | — | — | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | — | — | — | — | — | $484.7m | $653.3m | ($542.2m) | ($732.5m) | — | ($729.5m) | |
| Provision for income taxes | — | — | — | — | — | $0 | $0 | $1.2m | $435k | — | — | |
| Current Income Tax Expense | — | — | — | — | — | ($167k) | $0 | $0 | — | — | $3.3m | |
| Net loss | ($43.8m) | ($169.5m) | ($288.6m) | ($505.5m) | ($586.5m) | ($484.7m) | ($653.3m) | ($543.3m) | ($732.9m) | ($1.5m) | — | |
| Net loss for the year | — | — | — | ($19.6m) | ($36.4m) | ($12.2m) | ($9.4m) | ($2.9m) | ($3.6m) | ($1.5m) | — | |
| Net loss attributable | — | — | — | — | — | ($12.2m) | ($9.4m) | ($2.9m) | — | — | — | |
| Net loss attributable to common stockholders of BridgeBio | ($30.6m) | ($130.7m) | ($260.6m) | ($448.7m) | ($562.5m) | ($481.2m) | ($643.2m) | ($535.8m) | ($724.9m) | — | — | |
| Net Income (Loss) Available to Common Stockholders, Basic | ($30.6m) |
($130.7m)
-327.77%
|
($260.6m)
-99.30%
|
($448.7m)
-72.20%
|
($562.5m)
-25.36%
|
($481.2m)
+14.46%
|
($643.2m)
-33.67%
|
($535.8m)
+16.70%
|
($724.9m)
-35.31%
|
— | ($721.6m) | |
| Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests | $13.3m | $38.7m | $28.0m | $56.8m | $23.9m | $3.5m | $10.0m | $7.6m | $8.0m | — | — | |
| Net Income (Loss) Attributable to Noncontrolling Interest | $13.3m | ($38.7m) | ($28.0m) | ($56.8m) | ($23.9m) | ($3.5m) | ($10.0m) | ($7.6m) | ($8.0m) | — | ($721.6m) | |
| Net Income (Loss) Attributable to Nonredeemable Noncontrolling Interest | $13.3m | ($26.2m) | ($25.1m) | $56.8m | $23.9m | $3.5m | $10.0m | $7.6m | $8.0m | — | ($721.6m) | |
| Earnings Per Share, Basic | — | — | — | — | — | ($3.26) | ($3.95) | ($2.88) | ($3.78) | ($0.01) | ($3.74) | |
| Earnings Per Share, Diluted | — | — | — | — | — | ($3.26) | ($3.95) | ($2.88) | ($3.78) | ($0.01) | ($3.74) | |
| Weighted Average Number of Shares Outstanding, Basic | — | — | — | 15.0m | 27.0m | 147.5m | 162.8m | 186.1m | 191.5m | 145.9m | 192.7m | |
| Weighted Average Shares Outstanding | — | — | — | 15.0m | 27.0m | 75.5m | 86.6m | 109.3m | 123.9m | 145.9m | — | |
| Weighted Average Number of Shares Outstanding, Diluted | — | — | — | 15.0m | 27.0m | 147.5m | 162.8m | 186.1m | 191.5m | 145.9m | 192.7m | |
| Additional Financial Items | ||||||||||||
| Gain on deconsolidation of subsidiaries | — | $19.3m | — | — | — | $0 | $0 | $178.3m | $0 | — | — | |
| Loss on extinguishments of debt | — | — | — | — | — | $0 | $0 | ($26.6m) | ($21.2m) | — | — | |
| Consulting fees | — | — | — | $1.6m | $2.0m | $1.0m | $3.5m | $400k | $1.1m | $170k | — | |
| Foreign Currency Gain/Loss | — | — | — | $38k | ($39k) | $238k | $203k | $30k | $275k | ($201k) | — | |
| Professional fees | — | — | — | $1.7m | $1.4m | $879k | $895k | $527k | $499k | $265k | — | |
| Wages, salaries and employment expenses | — | — | — | $3.0m | $1.7m | $1.7m | $1.7m | $1.4m | $2.4m | $1.1m | — | |
| Accretion expense (Notes 5 and 6) | — | — | — | ($381k) | ($33k) | ($7k) | ($56k) | ($5k) | ($154k) | ($78k) | — | |
| Net Cash from Operating Activities | — | — | — | — | — | — | — | ($138k) |
($33k)
+75.73%
|
$198k
+691.95%
|
— | |
| Financial guarantee recovery (expense) (Note 16(c)) | — | — | — | — | ($182k) | ($1.2m) | ($24k) | ($34k) | $759k | ($30k) | — | |
| Gain on extinguishment/forgiveness of debts (Note 14) | — | — | — | — | — | — | $0 | $469k | $110k | $150k | — | |
| Gain on loan extinguishment (Note 6) | — | — | — | — | — | — | — | $0 | $0 | $10k | — | |
| Penalties recovery (expense) | — | — | — | — | — | ($344k) | $95k | ($34k) | $305k | $0 | — | |
| Settlements and legal provisions, net (Notes 14, 16(a) and 16(d)) | — | — | — | — | — | $56k | $258k | $130k | $557k | $0 | — | |
| Foreign Currency Translation Adjustments | — | — | — | — | — | — | — | ($5k) | ($31k) | $5k | — | |
| Comprehensive loss for the year | — | — | — | ($19.5m) | ($36.4m) | ($12.0m) | ($9.4m) | ($2.9m) | ($3.7m) | ($1.5m) | — | |
| Company's shareholders | — | — | — | — | — | ($12.2m) | ($9.0m) | ($2.9m) | ($3.5m) | ($1.5m) | — | |
| Non-controlling interests (Note 12) | — | — | — | — | — | $0 | ($357k) | ($9k) | ($102k) | ($17k) | — | |
| Depreciation Expense | — | — | — | — | — | $18k | $18k | $0 | $0 | — | — | |
| Changes in fair values of warrant liabilities (Notes 9(a) and 9(b)) | — | — | — | — | — | — | $5k | ($138k) | ($33k) | — | — | |
| Loss on debt modifications (Note 6) | — | — | — | — | — | — | ($197k) | $0 | $0 | — | — | |
| Foreign currency translation adjustment of foreign operations | — | — | — | $49k | ($62k) | $0 | ($18k) | ($5k) | ($31k) | — | — | |
| Promotion and marketing | — | — | — | $97k | $186k | $438k | $123k | $0 | — | — | — | |
| Change in unrealized (losses) gains on warrant liabilities (Notes 10(a) and 10(b)) | — | — | — | — | — | $131k | $5k | ($138k) | — | — | — | |
| Financial guarantee expense (Note 18(c)) | — | — | — | — | ($182k) | ($1.2m) | ($24k) | ($34k) | $759k | ($30k) | — | |
| (Loss) gain on debt modifications (Note 7) | — | — | — | — | — | $56k | ($197k) | $0 | — | — | — | |
| Other | — | — | — | $48k | ($40k) | $27k | $18k | ($945) | $9 | ($679) | — | |
| Settlements and legal provisions, net (Notes 15 and 18) | — | — | — | ($265k) | ($120k) | ($563k) | $258k | $130k | — | — | — | |
| Net comprehensive loss attributable | — | — | — | — | — | ($12.0m) | ($9.4m) | ($5k) | — | — | — | |
| Amortization and depreciation of equipment and intangible assets (Notes 8 and 9) | — | — | — | $986k | $158k | $18k | — | — | — | — | — | |
| Amortization of right-of-use assets (Note 10) | — | — | — | $362k | ($70k) | — | — | — | — | — | — | |
| Lease liability expense (Note 10) | — | — | — | $347k | $479k | — | — | — | — | — | — | |
| Repairs and maintenance | — | — | — | $46k | $23k | — | — | — | — | — | — | |
| Change in unrealized gains/losses on warrant liabilities (Note 13(a)) | — | — | — | — | ($74k) | ($131k) | — | — | — | — | — | |
| Loss on impairment of intangible assets (Note 9) | — | — | — | ($6.6m) | ($12.1m) | — | — | — | — | — | — | |
| Total expenses | — | — | — | $9.3m | $7.9m | $10.2m | $9.5m | $3.2m | $5.0m | $1.6m | $1.1b |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.